Veterinary Medicine Market Size, Share & Trends Analysis Report By Product (Biologics, Pharmaceuticals), By Animal Type, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
2025 - 2030 年兽药市场规模、份额及趋势分析报告（按产品（生物制剂、药品）、动物类型、给药途径、分销渠道、地区和细分市场预测）

Veterinary Medicine Market Size & Trends
兽药市场规模及趋势

The global veterinary medicine market size was estimated at USD 49.96 billion in 2024 and is projected to grow at a CAGR of 8.5% from 2025 to 2030. The market is driven by increasing demand for animal protein, incidence of diseases in animals, and product launches. Other factors fueling market growth include advancements in veterinary medicine and penetration of pet insurance. For instance, In August 2024, Elanco Animal Health announced that the FDA had completed its review of Credelio Quattro, its new broad-spectrum parasiticide, and is now in the final 60-day administrative review stage. The Product, which targets fleas, ticks, heartworms, and other internal parasites, is expected to receive U.S. approval by the end of October 2024 and launch in the first quarter of 2025.
2024年全球兽药市场规模估计为499.6亿美元，预计2025年至2030年复合年增长率为8.5%。该市场是由动物蛋白需求增加、动物疾病发生率和产品推出推动的。推动市场增长的其他因素包括兽医学的进步和宠物保险的普及。例如，2024年8月，Elanco Animal Health宣布FDA已完成对其新型广谱杀虫剂Credelio Quattro的审查，目前正处于最后的60天行政审查阶段。该产品针对跳蚤、蜱虫、心丝虫和其他体内寄生虫，预计将于 2024 年 10 月底获得美国批准，并于 2025 年第一季度推出。

To learn more about this report, request a free sample copy
要了解有关此报告的更多信息，请索取免费样本副本

In addition, rising government initiatives play a significant role in driving the market's growth. These initiatives aim to enhance animal welfare, ensure food safety, prevent disease spread, and promote sustainable agriculture. Governments establish regulations and standards for the approval, manufacturing, distribution, and use of veterinary pharmaceuticals, vaccines, & feed additives. Regulatory agencies ensure that products meet safety, efficacy, and quality standards, which provides assurance to consumers and promotes trust in animal health products. In the U.S., the FDA and other bodies, such as the United States Department of Agriculture (USDA), regulate the animal health market. In March 2024, the FDA approved Dechra’s DuOtic under the New Animal Drug Applications for treating otitis externa in dogs. In March 2024, the FDA also approved CONTRASED by Parnell Technologies Pty. Ltd. under the Abbreviated New Animal Drug Application (ANADA) process for the reversal of the sedative and analgesic effects of medetomidine hydrochloride and dexmedetomidine hydrochloride in dogs.
此外，政府不断采取的举措在推动市场增长方面发挥着重要作用。这些举措旨在提高动物福利、确保食品安全、防止疾病传播并促进可持续农业。政府制定兽药、疫苗和饲料添加剂的审批、生产、分销和使用的法规和标准。监管机构确保产品符合安全性、功效和质量标准，这为消费者提供了保证并促进了对动物保健产品的信任。在美国，FDA 和美国农业部 (USDA) 等其他机构负责监管动物保健市场。 2024 年 3 月，FDA 根据新动物药物申请批准了 Dechra 的 DuOtic 用于治疗狗的外耳炎。 2024年3月，FDA还根据简化新动物药物申请（ANADA）流程批准了Parnell Technologies Pty. Ltd.的CONTRASED，用于逆转盐酸美托咪定和盐酸右美托咪定对狗的镇静和镇痛作用。

The overall animal health sector, including veterinary medicine, turned out to be resilient despite many challenges and is expected to grow significantly over the forecast period owing to underlying solid drivers. According to a report by the Australian Bureau of Agriculture and Resources Economics and Sciences, China will represent around 40% of the increase in meat demand by 2050. As per the OECD 2022-2031 agricultural outlook, global pig meat consumption is forecast to reach 129 metric tons in the next 10 years, which is expected to account for one-third of total meat consumption. This increasing consumption is expected to fuel demand for safe food sources, highlighting biosecurity and prudent use of veterinary medicines. This is anticipated to propel market growth in the near future.
尽管面临许多挑战，包括兽医在内的整个动物保健行业仍然具有弹性，并且由于潜在的坚实驱动因素，预计在预测期内将大幅增长。根据澳大利亚农业与资源经济与科学局的一份报告，到2050年，中国将占肉类需求增量的40%左右。根据经合组织2022-2031年农业展望，全球猪肉消费量预计将达到129预计未来10年将占肉类消费总量的三分之一。消费量的增加预计将刺激对安全食品来源的需求，凸显生物安全和兽药的谨慎使用。预计这将在不久的将来推动市场增长。

Report Coverage & Deliverables
报告范围和交付成果

PDF report & online dashboard will help you understand:
PDF 报告和在线仪表板将帮助您了解：

• Competitive benchmarking 竞争标杆管理
• Historical data & forecasts
  历史数据和预测
• Company revenue shares 公司收入份额
• Regional opportunities 区域机会
• Latest trends & dynamics 最新趋势和动态

View Data On Platform 查看平台数据

Explore Sample Data 探索样本数据

Market Concentration & Characteristics
市场集中度及特点

The market for veterinary medicine is moderately concentrated, with a few key players dominating the industry. Major companies such as Zoetis, Elanco, Merck Animal Health, and Boehringer Ingelheim collectively hold a significant market share, accounting for over 50% of total sales. This concentration allows these companies to utilize economies of scale and invest heavily in research and development, driving innovation and product offerings in veterinary medicine. In addition, emerging companies and niche players are also entering the market, particularly in segments such as biologics and specialty therapeutics, contributing to a growing diversity of products. The market is expected to witness increased consolidation as key players acquire smaller companies to enhance their product offerings and expand into new geographical regions. In addition, the trend toward personalized medicine and advanced therapies, such as monoclonal antibodies, encourages innovation and competition among existing players, further shaping the market landscape.
兽药市场集中度中等，少数主要企业占据主导地位。 Zoetis、Elanco、Merck Animal Health、Boehringer Ingelheim等大公司共同占有重要的市场份额，占总销售额的50%以上。这种集中使这些公司能够利用规模经济并大力投资于研发，推动兽药领域的创新和产品供应。此外，新兴公司和利基市场参与者也正在进入市场，特别是在生物制剂和特殊治疗药物等领域，从而促进了产品的日益多样化。随着主要参与者收购较小的公司以增强其产品供应并扩展到新的地理区域，预计市场将出现更多的整合。此外，个性化医疗和单克隆抗体等先进疗法的趋势鼓励现有参与者之间的创新和竞争，进一步塑造市场格局。

Advancements in animal preventive and therapeutic treatments, such as new drugs and procedures, contribute to innovation. Ongoing research and development efforts, collaboration between academia and industry, regulatory frameworks, and the evolving needs of the veterinary community and animal owners influence the degree of innovation. As technology and scientific knowledge continue to advance, the veterinary medicine market is likely to see further innovations that improve the quality of care for animals.
动物预防和治疗方面的进步（例如新药物和新程序）有助于创新。持续的研究和开发工作、学术界和工业界之间的合作、监管框架以及兽医界和动物所有者不断变化的需求都会影响创新的程度。随着技术和科学知识的不断进步，兽药市场可能会出现进一步的创新，以提高动物护理质量。

To learn more about this report, request a free sample copy
要了解有关此报告的更多信息，请索取免费样本副本

M&A activities are often initiated by market players driven by the desire to achieve economies of scale, improve operational efficiency, expand their geographic reach, or gain access to new markets and strengthen market presence. In September 2024, Boehringer Ingelheim acquired Saiba Animal Health AG, enhancing its R&D capabilities in pet therapeutics, particularly for chronic conditions. This acquisition strengthens Boehringer's R&D and sets a precedent in developing long-lasting, immune-based treatments, which could become a new standard in managing chronic diseases in pets. M&As increase investment in veterinary health, introduce new technologies faster, and foster a more competitive market, improving care standards and expanding options available to veterinarians and pet owners.
并购活动通常是由市场参与者出于实现规模经济、提高运营效率、扩大地理覆盖范围或进入新市场和加强市场影响力的愿望而发起的。 2024年9月，勃林格殷格翰收购了Saiba Animal Health AG，增强了其在宠物治疗尤其是慢性疾病治疗方面的研发能力。此次收购加强了勃林格殷格翰的研发能力，并开创了开发长效免疫疗法的先例，这可能成为治疗宠物慢性病的新标准。并购增加了对兽医健康的投资，更快地引入新技术，培育更具竞争力的市场，提高护理标准并扩大兽医和宠物主人的选择。

Regulations are crucial in shaping and influencing the market. These regulations are designed to ensure the safety and efficacy of veterinary products, protect animal health and welfare, and safeguard public health. Regulatory agencies, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), oversee the approval and registration of veterinary medicines. Strict regulatory requirements ensure that products meet safety and efficacy standards before marketing. The approval process can affect the time and cost of bringing new products to market. The impact of regulations on the market is thus medium to high.
法规对于塑造和影响市场至关重要。这些法规旨在确保兽药产品的安全性和有效性，保护动物健康和福利，并保障公众健康。美国食品药品监督管理局 (FDA) 和欧洲药品管理局 (EMA) 等监管机构负责监督兽药的审批和注册。严格的监管要求确保产品在上市前符合安全性和功效标准。审批流程会影响新产品上市的时间和成本。因此，监管对市场的影响是中度到高度。

Companies focus on product portfolio expansion by investing in R&D and partnerships. Market players are involved in diversifying product lines. For instance, in April 2024, Phibro Animal Health reached a definitive agreement to acquire a medicated feed additive (MFA) portfolio from Zoetis and related assets for $350 million. This acquisition includes over 37 product lines and six manufacturing sites and is expected to enhance Phibro's animal care and nutrition offerings, potentially boosting its profitability. Phibro Animal Health's product expansion strengthens its market position and enhances veterinary medicine by providing practical, diverse, and sustainable treatment options that improve animal health and productivity.
公司通过投资研发和合作伙伴关系来专注于产品组合的扩展。市场参与者致力于产品线多元化。例如，2024 年 4 月，Phibro Animal Health 达成最终协议，以 3.5 亿美元收购 Zoetis 的药物饲料添加剂 (MFA) 产品组合及相关资产。此次收购包括超过 37 条产品线和 6 个生产基地，预计将增强 Phibro 的动物护理和营养产品，从而有可能提高其盈利能力。 Phibro Animal Health 的产品扩张增强了其市场地位，并通过提供实用、多样化和可持续的治疗方案来改善动物健康和生产力，从而增强了兽医医学。

Companies are expanding their regional reach to increase market presence and share. Expanding into new areas allows companies to introduce customized products that address specific regional health issues and comply with local regulatory standards, which is essential in addressing global veterinary needs. For Instance, in August 2024, Elanco Animal Health announced a $130 million investment to expand its biologics manufacturing facility in Elwood, Kansas, to develop its monoclonal antibody (mAb) platform. This expansion will boost production capacity, introduce new processing equipment, and create approximately 70 jobs over the next two years. The facility is pivotal for developing Elanco's Canine Parvovirus Monoclonal Antibody (CPMA) and future mAb therapies, emphasizing the growing significance of antibody-based treatments in the animal health industry.
公司正在扩大其区域影响力，以提高市场占有率和份额。扩展到新领域使公司能够推出解决特定区域健康问题并符合当地监管标准的定制产品，这对于满足全球兽医需求至关重要。例如，2024 年 8 月，Elanco Animal Health 宣布投资 1.3 亿美元，扩建其位于堪萨斯州埃尔伍德的生物制品生产设施，以开发其单克隆抗体 (mAb) 平台。此次扩建将提高产能，引进新的加工设备，并在未来两年内创造约 70 个就业岗位。该设施对于开发 Elanco 的犬细小病毒单克隆抗体 (CPMA) 和未来的单克隆抗体疗法至关重要，强调了基于抗体的治疗在动物健康行业中日益重要的意义。

Product Insights 产品洞察

In 2024, the pharmaceuticals segment held the largest revenue share of 67.38% of the market. Pharmaceuticals primarily include anti-inflammatory drugs, parasiticides, anti-infectives, and others. The segment growth can be attributed to a combination of factors, including increasing pet ownership, technological advancements, growing awareness of animal health, investments in R&D, and a shift towards preventive healthcare. Pharmaceutical companies invest heavily in R&D activities to introduce new and improved veterinary medicines. For instance, in 2023, Boehringer Ingelheim launched four essential products: SENVELGO for diabetic cats, NexGard PLUS for comprehensive protection against fleas, ticks, and heartworm in dogs, NexGard COMBO for similar parasite control, and FRONTPRO, a non-prescription chewable for flea and tick control in dogs. These new offerings significantly contributed to the company's sales growth.
2024年，药品领域占据最大的收入份额，占市场的67.38%。药品主要包括抗炎药、杀寄生虫药、抗感染药等。该细分市场的增长可归因于多种因素的综合作用，包括宠物拥有量的增加、技术进步、动物健康意识的增强、研发投资以及向预防性医疗保健的转变。制药公司大力投资研发活动，以推出新的和改进的兽药。例如，2023年，勃林格殷格翰推出了四种基本产品：用于糖尿病猫的SENVELGO、用于全面预防狗跳蚤、蜱虫和心丝虫的NexGard PLUS、用于控制类似寄生虫的NexGard COMBO以及用于跳蚤的非处方咀嚼片FRONTPRO以及狗的蜱虫控制。这些新产品极大地促进了公司的销售增长。

The biologics segment is anticipated to witness the fastest CAGR from 2025 to 2030. The growth of this market can be attributed to increasing animal health expenditure, availability of veterinary medicines, R&D activities, product launches by key companies, and the rising prevalence of diseases in animals. For instance, in July 2024, ELIAS Animal Health launched a clinical study to evaluate its ELIAS Cancer Immunotherapy (ECI) in combination with an innovative adjuvant as a limb-sparing treatment for large-breed dogs with appendicular osteosarcoma. This study was funded by the Morris Animal Foundation to assess the safety and efficacy of this approach, which could provide alternatives to amputation for eligible breeds, offering hope for improved quality of life for affected dogs.
预计从 2025 年到 2030 年，生物制品领域的复合年增长率将是最快的。该市场的增长可归因于动物保健支出的增加、兽药的供应、研发活动、主要公司的产品发布以及疾病患病率的上升。动物。例如，2024 年 7 月，ELIAS Animal Health 启动了一项临床研究，评估其 ELIAS 癌症免疫疗法 (ECI) 与创新佐剂相结合，作为患有阑尾骨肉瘤的大型犬的肢体保留治疗。这项研究由莫里斯动物基金会资助，旨在评估这种方法的安全性和有效性，该方法可以为符合条件的品种提供截肢的替代方案，为改善受影响狗的生活质量带来希望。

Animal Type Insights 动物类型见解

The production animals segment held the largest revenue share in 2024. This is owing to the high uptake of medicines in the livestock sector, the need for disease prevention & control, and the intensification of livestock farming; as the global population continues to grow, so does the demand for animal products such as meat, milk, and dairy products. This puts pressure on the livestock industry to increase production, leading to a greater need for veterinary medicine to ensure the health and well-being of animals.
2024年，生产性动物部门占据最大的收入份额。这是由于畜牧业药物的大量使用、疾病预防和控制的需要以及畜牧业的集约化；随着全球人口持续增长，对肉类、牛奶和乳制品等动物产品的需求也在增长。这给畜牧业带来了增加产量的压力，导致对兽药的需求更大，以确保动物的健康和福祉。

The companion animal segment is expected to grow lucratively during the forecast period owing to increased pet ownership, humanization of pets, and expenditure of pets. Dogs and cats are the most popular pets. The growing availability of canine and feline medicines and a strong R&D pipeline are estimated to propel segment growth in the coming years. In September 2024, Elanco Animal Health launched Zenrelia, a once-daily oral JAK inhibitor approved by the FDA for managing allergic and atopic dermatitis in dogs. The introduction of Zenrelia reflects Elanco's commitment to expanding treatment options in veterinary medicine, enhancing the well-being of pets and their owners. Similarly, Dechra in September 2024 introduced Furosoral, a new diuretic for cats and dogs, designed to treat fluid retention associated with conditions like hydrothorax, hydropericardium, ascites, and edema, particularly in cases related to cardiac and renal issues.
由于宠物拥有量的增加、宠物的人性化和宠物支出的增加，预计伴侣动物市场在预测期内将出现利润丰厚的增长。狗和猫是最受欢迎的宠物。犬类和猫类药物的供应量不断增加以及强大的研发渠道预计将在未来几年推动该细分市场的增长。 2024 年 9 月，Elanco Animal Health 推出了 Zenrelia，这是一种每日一次的口服 JAK 抑制剂，经 FDA 批准用于治疗狗的过敏性和特应性皮炎。 Zenrelia 的推出体现了 Elanco 致力于扩大兽医治疗选择、提高宠物及其主人的福祉的承诺。同样，Dechra 于 2024 年 9 月推出了 Furosoral，这是一种针对猫和狗的新型利尿剂，旨在治疗与胸水、心包积水、腹水和水肿等疾病相关的液体潴留，特别是与心脏和肾脏问题相关的病例。

Distribution Channel Insights
分销渠道洞察

The veterinary hospitals & clinics segment held the largest revenue share in 2024. These facilities play a pivotal role in providing healthcare services to animals and are well-positioned to integrate veterinary medicines into a broader spectrum of care, addressing both acute and chronic conditions in animals. Moreover, these facilities typically have in-house pharmacies or partnerships with external pharmacies to dispense prescribed veterinary medicines directly to animal owners. This ensures a seamless process from diagnosis to treatment.
兽医医院和诊所部门在 2024 年占据最大的收入份额。这些设施在为动物提供医疗保健服务方面发挥着关键作用，并且处于有利地位，可以将兽药整合到更广泛的护理中，解决动物的急性和慢性疾病。此外，这些设施通常拥有内部药房或与外部药房合作，直接向动物主人分发处方兽药。这确保了从诊断到治疗的无缝过程。

Veterinary hospitals and clinics also build ongoing relationships with pet owners or livestock producers. This fosters trust and communication, creating an environment where clients are more likely to follow prescribed treatment plans. The continuity of care is reinforced by obtaining medications directly from the same facility where animals receive other veterinary services. The E-commerce segment, on the other hand, is estimated to register the fastest CAGR over the forecast period. This is owing to the convenience of ordering medicines online, wide product selection, price comparison, and competitive pricing offered by e-commerce platforms.
兽医医院和诊所还与宠物主人或牲畜生产者建立持续的关系。这促进了信任和沟通，创造了一个让客户更有可能遵循规定的治疗计划的环境。通过直接从动物接受其他兽医服务的同一机构获取药物，可以加强护理的连续性。另一方面，电子商务领域预计在预测期内复合年增长率最快。这是由于电子商务平台提供在线订购药品的便利性、广泛的产品选择、价格比较和有竞争力的价格。

Route of Administration Insights
管理途径见解

The injectable segment dominated the market in 2024 in terms of revenue share. The segment comprises drugs administered via intravenous, intramuscular, & subcutaneous routes. The availability of numerous injectable medicines, the high cost of injections, and the benefits associated with the injectable route are some of the key factors driving market growth. The injectable route facilitates the rapid onset of action, precise dosage control, and higher drug bioavailability, contributing to its growing adoption. In May 2023, Zoetis received FDA clearance for Librela-its injectable anti-nerve growth factor (NGF) monoclonal antibody (mAb) for osteoarthritic dogs.
就收入份额而言，注射剂细分市场将在 2024 年占据市场主导地位。该部分包括通过静脉内、肌内和皮下途径给药的药物。众多注射药物的可用性、注射的高成本以及与注射途径相关的好处是推动市场增长的一些关键因素。注射途径有利于快速起效、精确的剂量控制和更高的药物生物利用度，有助于其日益普及。 2023 年 5 月，硕腾的 Librela 获得 FDA 批准——其用于骨关节炎犬的可注射抗神经生长因子（NGF）单克隆抗体（mAb）。

To learn more about this report, request a free sample copy
要了解有关此报告的更多信息，请索取免费样本副本

Other route segments include inhalational routes and controlled-release implants. This segment is expected to grow at the fastest CAGR from 2025 to 2030 due to the increasing availability of products and the growing adoption of alternative modes of delivery by livestock farmers & pet parents. For instance, REVALOR-XS by Merck & Co., Inc. is an extended-release implant containing trenbolone acetate and estradiol that improves feed efficiency and increases the rate of weight gain in cattle.
其他途径部分包括吸入途径和控释植入剂。由于产品可用性的增加以及畜牧养殖户和宠物父母越来越多地采用替代交付方式，预计该细分市场从 2025 年到 2030 年将以最快的复合年增长率增长。例如，Merck & Co., Inc. 的 REVALOR-XS 是一种含有醋酸群勃龙和雌二醇的缓释植入剂，可提高饲料效率并增加牛的体重增加率。

Regional Insights  区域洞察

The North America veterinary medicine market held the largest revenue share globally in 2024. This can be attributed to the presence of key companies, high expenditure on pets, pet humanization, and rising awareness about animal disease. For instance, key market players, such as Zoetis, Merck & Co., Inc., Elanco Animal Health, and Vetbiologics, are headquartered in the U.S. and are undertaking various strategic initiatives to increase their market share. In September 2023, Elanco launched Varenzi-CA1- its U.S. FDA conditionally approved Product- to control non-regenerative anemia in felines with chronic kidney disease (CKD).
2024年，北美兽药市场在全球占据最大的收入份额。这可以归因于主要公司的存在、宠物的高支出、宠物人性化以及对动物疾病的认识不断提高。例如，硕腾 (Zoetis)、默克公司 (Merck & Co., Inc.)、Elanco Animal Health 和 Vetbiologics 等主要市场参与者的总部位于美国，并正在采取各种战略举措来增加其市场份额。 2023 年 9 月，Elanco 推出了其美国 FDA 有条件批准的产品 Varenzi-CA1，用于控制患有慢性肾病 (CKD) 的猫科动物的非再生性贫血。

To learn more about this report, request a free sample copy
要了解有关此报告的更多信息，请索取免费样本副本

U.S. Veterinary Medicine Market Trends
美国兽药市场趋势

The veterinary medicine market in U.S. is driven by rising incidences of zoonotic diseases, increased livestock population, growing focus on preventive care, advancements in pet medicine, and increasing pet ownership. According to the October 2024 report released by the American Pet Products Association (APPA), 59.8 million households in the U.S. own a dog, and 42.1 million families own cats. Furthermore, the livestock population has increased, with significant growth in cattle, sheep, pigs, and poultry being raised for meat production. For instance, as of January 2024, the U.S. had 87.8 million cattle and 74.97 million swine stock, according to the U.S. Foreign Agricultural Service’s Livestock and Poultry: World Markets and Trade report. This substantial livestock population necessitates comprehensive veterinary care and medical interventions to maintain health and productivity.
美国兽药市场的推动因素包括人畜共患疾病发病率上升、牲畜数量增加、对预防保健的日益关注、宠物医学的进步以及宠物拥有量的增加。根据美国宠物用品协会（APPA）2024年10月发布的报告，美国有5980万个家庭养狗，4210万个家庭养猫。此外，牲畜数量有所增加，用于肉类生产的牛、羊、猪和家禽的饲养量显着增加。例如，根据美国对外农业服务局的畜禽：世界市场和贸易报告，截至 2024 年 1 月，美国拥有 8780 万头牛和 7497 万头猪。如此庞大的牲畜数量需要全面的兽医护理和医疗干预措施来维持健康和生产力。

Europe Veterinary Medicine Market Trends
欧洲兽药市场趋势

The veterinary medicine market in Europe has some of the world's most stringent animal welfare regulations. Compliance with these regulations necessitates using veterinary medicines to ensure the health and welfare of animals, whether they are companion animals or part of the livestock sector. The region is also characterized by a well-developed veterinary healthcare infrastructure. Ongoing technological advancements, including the development of innovative medicines, diagnostic tools, and treatment modalities, contribute to the growth of the market as practitioners adopt new and improved methods of care.
欧洲兽药市场拥有一些世界上最严格的动物福利法规。遵守这些法规需要使用兽药来确保动物的健康和福利，无论它们是伴侣动物还是畜牧业的一部分。该地区的另一个特点是拥有发达的兽医保健基础设施。随着从业者采用新的和改进的护理方法，不断的技术进步，包括创新药物、诊断工具和治疗方式的开发，有助于市场的增长。

The veterinary medicine market in Germany is driven by rising animal adoption & cattle population, increasing preventative care for animals, and growing awareness about the significance of the health of farm & companion animals in the country. For instance, according to the German Livestock, the country has the largest dairy cattle herd & the second-largest cattle population in the European Union (EU). Furthermore, according to the International Committee for Animal Recording (ICAR), 50% of German farms specialize in livestock, which is anticipated to drive the veterinary medicine market.
德国兽药市场的推动因素包括动物收养和牛群数量的增加、动物预防性护理的增加以及对该国农场和伴侣动物健康重要性的认识不断提高。例如，根据德国畜牧业协会的数据，该国拥有欧盟 (EU) 最大的奶牛群和第二大牛群。此外，根据国际动物记录委员会 (ICAR) 的数据，50% 的德国农场专门饲养牲畜，预计这将推动兽药市场的发展。

Moreover, according to a survey commissioned by Industrieverband Heimtierbedarf (IVH) e.V., 44% of all households in Germany have at least one domestic animal. Rising partnerships and acquisitions among major players in the country drive the market. For instance, in September 2023, Zoetis acquired a German biotech company, adivo. The acquisition would provide Zoetis access to technological & existing species-specific antibody libraries and the opportunity to develop numerous novel veterinary products.
此外，根据 Industrieverband Heimtierbedarf (IVH) eV 委托进行的一项调查显示，44% 的德国家庭至少拥有一只家畜。该国主要参与者之间不断增加的合作伙伴关系和收购推动了市场的发展。例如，2023年9月，硕腾收购了德国生物科技公司adivo。此次收购将使硕腾能够获得技术和现有的物种特异性抗体库，并有机会开发众多新型兽药产品。

Asia Pacific Veterinary Medicine Market Trends
亚太地区兽药市场趋势

The Asia Pacific veterinary medicine market is expected to witness the fastest CAGR over the forecast period. As economies in the Asia Pacific region continue to grow, there is a noticeable increase in the size of the middle-class population, higher disposable incomes, and growing urbanization. This is associated with lifestyle changes, including a growing preference for companion animals. Urban dwellers often seek veterinary care for their pets, contributing to the demand for various veterinary medicines, preventive treatments, and healthcare services. Market players have begun to capture opportunities in these emerging markets. The abundant growth of opportunities in Indian animal health has, in recent years, attracted many new entrants into the market. For instance, in January 2024, ENTOD Pharmaceuticals, one of the leading announced entries into the veterinary sector with the launch of “Fur,” a range of veterinary ophthalmic medicines ranging from lubricating eye drops, anti-allergic drugs, antibiotics, as well as anti-glaucoma medications. Furthermore, in August 2024, Godrej Consumer products announced an investment of over INR 500 crore (USD 60 million) over the next five years into a new pet care business in India.
预计亚太地区兽药市场将在预测期内实现最快的复合年增长率。随着亚太地区经济持续增长，中产阶级人口规模显着增加，可支配收入提高，城市化进程不断加快。这与生活方式的改变有关，包括对伴侣动物的日益偏好。城市居民经常为他们的宠物寻求兽医护理，从而增加了对各种兽药、预防治疗和医疗保健服务的需求。市场参与者已经开始抓住这些新兴市场的机遇。近年来，印度动物保健领域的大量增长机会吸引了许多新进入者。例如，2024 年 1 月，领先的 ENTOD Pharmaceuticals 宣布进军兽医领域，推出了“Fur”，这是一系列兽用眼科药物，包括润滑滴眼剂、抗过敏药物、抗生素以及抗青光眼药物。此外，2024 年 8 月，Godrej Consumer products 宣布未来五年投资超过 50 亿印度卢比（6000 万美元），在印度开展新的宠物护理业务。

The veterinary medicine market in India is expected to grow at a CAGR of 10.5% over the forecast period due to the rising livestock production, growing dairy industry, and supportive strategic initiatives by key players. Companies like Zoetis, Merck Animal Health, and Elanco are increasingly investing in India, establishing R&D centers, and enhancing production capabilities to meet rising domestic demand. This growth is fueled by India’s skilled workforce, cost-effective operations, and thriving livestock sector, making it an attractive destination for veterinary innovations. For instance, in September 2024, Zoetis expanded its Global Capability Center in Hyderabad, India, strengthening its commitment to utilizing India's skilled workforce for global innovation in animal health. This expansion will create hundreds of advanced technology roles in AI, Machine Learning, and Data Science, aligning with Zoetis' strategy to strengthen R&D and digital capabilities.
由于牲畜产量的增加、乳制品行业的发展以及主要参与者的支持性战略举措，预计印度兽药市场在预测期内将以 10.5% 的复合年增长率增长。 Zoetis、默克动物保健和Elanco等公司越来越多地在印度投资，建立研发中心，并提高生产能力，以满足不断增长的国内需求。印度熟练的劳动力、具有成本效益的运营和蓬勃发展的畜牧业推动了这一增长，使其成为兽医创新的有吸引力的目的地。例如，2024 年 9 月，硕腾扩大了位于印度海得拉巴的全球能力中心，加强了其利用印度熟练劳动力进行动物健康全球创新的承诺。此次扩张将在人工智能、机器学习和数据科学领域创造数百个先进技术职位，与硕腾加强研发和数字能力的战略保持一致。

Latin America Veterinary Medicine Market Trends
拉丁美洲兽药市场趋势

The veterinary medicine market In Latin America is driven by the growth in the livestock sector, including cattle, poultry, and swine, which necessitates the use of veterinary medicines for disease prevention, treatment, and overall herd health management. Livestock producers seek effective veterinary solutions to enhance the productivity of their animals and ensure a stable and reliable supply of meat and dairy products to meet the dietary needs of the growing population. In the MEA, food security concerns play a crucial role in driving the market growth. Governments and stakeholders recognize the importance of a robust and sustainable livestock sector to ensure a stable food supply. Veterinary medicines are thus essential in maintaining livestock's health and well-being, preventing disease outbreaks, and supporting the production of safe and abundant animal-derived food products.
拉丁美洲的兽药市场是由畜牧业（包括牛、家禽和猪）的增长推动的，这需要使用兽药来预防、治疗和整体牛群健康管理。畜牧生产者寻求有效的兽医解决方案，以提高动物的生产力，并确保稳定可靠的肉类和乳制品供应，以满足不断增长的人口的饮食需求。在多边环境协定中，食品安全问题在推动市场增长方面发挥着至关重要的作用。各国政府和利益相关者认识到强大和可持续的畜牧业对于确保稳定的粮食供应的重要性。因此，兽药对于维持牲畜的健康和福祉、预防疾病爆发以及支持安全和丰富的动物源性食品的生产至关重要。

The veterinary medicine market in Brazil is growing due to rising mandates for vaccination to curb livestock disease outbreaks and increasing demand for livestock-related food products. Brazil's veterinary medicine market growth can be attributed to a large cattle population. For instance, according to Agro Concept Management Ltd, Brazil had the second-largest cattle herd, accounting for 232 million heads. Moreover, the country is also the world's largest exporter of beef. This has resulted in greater awareness of animal health and, subsequently, boosted the demand for veterinary medicines in the country.
由于遏制牲畜疾病爆发的疫苗接种要求不断增加以及对牲畜相关食品的需求不断增加，巴西的兽药市场正在增长。巴西兽药市场的增长可归因于大量的牛群。例如，根据 Agro Concept Management Ltd 的数据，巴西拥有第二大牛群，达 2.32 亿头。此外，该国还是世界上最大的牛肉出口国。这提高了人们对动物健康的认识，从而增加了该国对兽药的需求。

Middle East & Africa Veterinary Medicine Market Trends
中东和非洲兽药市场趋势

The Middle East & Africa (MEA) veterinary medicine market constitutes South Africa, Saudi Arabia, UAE, Kuwait, Egypt, and Israel. In the Middle East & Africa, the increasing adoption of veterinary services drives the veterinary medicines market. The growing prevalence of infectious diseases in animals increases the demand for veterinary treatments and medicines. A study published in January 2024 in the Journal of Tropical Medicine & Infectious Diseases examined rabies trends in South African animals from 1998 to 2022. Studies showed a significant rise in rabies cases, with companion animals like dogs, cats, and horses experiencing a 59% increase and livestock, including cattle, pigs, goats, and sheep, seeing over a 21% rise. The spread of animal pathogens due to the increasing international trade drives the demand for veterinary medicines. The shortage of veterinary vaccines is another major factor that drives the veterinary medicines market, resulting in increased import of veterinary vaccines. In addition, the rise in the adoption of livestock and poultry in MEA impels the regional market growth.
中东和非洲（MEA）兽药市场包括南非、沙特阿拉伯、阿联酋、科威特、埃及和以色列。在中东和非洲，兽医服务的日益普及推动了兽药市场的发展。动物传染病的日益流行增加了对兽医治疗和药物的需求。 2024 年 1 月发表在《热带医学与传染病杂志》上的一项研究调查了 1998 年至 2022 年南非动物的狂犬病趋势。研究显示狂犬病病例显着增加，狗、猫和马等伴侣动物的狂犬病病例增加了 59%牲畜，包括牛、猪、山羊和绵羊，增幅超过 21%。国际贸易的增加导致动物病原体的传播推动了对兽药的需求。兽用疫苗短缺是推动兽药市场的另一大因素，导致兽用疫苗进口增加。此外，中东和非洲地区畜禽饲养量的增加也推动了区域市场的增长。

The South Africa veterinary medicine market is driven by the rising incidence of diseases and major outbreaks. According to an FAO report published on October 2024, Since February 2017, Sub-Saharan Africa has faced outbreaks of high pathogenic avian influenza (HPAI) subtypes, including H5, H5N1, H5N2, H5N6, H5N8, H7, and H7N6. As of October 2024, South Africa, among other countries, has reported numerous cases across various regions, with significant impacts on poultry and other bird species. The increasing prevalence of similar diseases across animal types is expected to propel the demand for veterinary medicines, such as pharmaceuticals and biologics.
南非兽药市场受到疾病发病率上升和重大疫情的推动。根据联合国粮农组织2024年10月发布的报告，自2017年2月以来，撒哈拉以南非洲地区爆发了高致病性禽流感（HPAI）亚型，包括H5、H5N1、H5N2、H5N6、H5N8、H7和H7N6。截至 2024 年 10 月，南非等国家在不同地区报告了多起病例，对家禽和其他鸟类产生了重大影响。动物类型中类似疾病的日益流行预计将推动对兽药（例如药品和生物制品）的需求。

Furthermore, according to an April 2024 article in Dogster, dog ownership is prevalent in South Africa, with over 78% of pet owners having at least one dog. Additionally, more than 45% of households in the country own some type of pet, indicating a growing trend in pet adoption. This increasing popularity has increased the demand for veterinary medications and treatment services. Pet owners in South Africa typically spend between USD 1,800 and 4,000 annually on their pets, further emphasizing the growing investment in pet care.
此外，根据 Dogster 2024 年 4 月的一篇文章，南非养狗现象很普遍，超过 78% 的宠物主人至少养一只狗。此外，该国超过 45% 的家庭拥有某种类型的宠物，这表明收养宠物的趋势不断增长。这种日益普及增加了对兽药和治疗服务的需求。南非的宠物主人每年通常在宠物身上花费 1,800 至 4,000 美元，这进一步凸显了宠物护理投资的不断增长。

Key Veterinary Medicine Company Insights
主要兽药公司见解

The presence of several small and large companies leads to a competitive market. These companies offer a wide range of veterinary medicines across segments and target species. Furthermore, market players are deploying various strategic initiatives, such as R&D, mergers & acquisitions, regional expansion, partnerships, & collaborations, to support their growth objectives. For instance, in August 2024, Elanco Animal Health is investing $130 million to expand its biologics manufacturing facility in Elwood, Kansas, by 25,000 sq ft, enhancing its monoclonal antibody (mAb) platform. This expansion, expected to generate 70 new jobs by 2026, will support the production of Canine Parvovirus Monoclonal Antibody and future mAb therapies in canine dermatology, emphasizing the industry's shift toward antibody-based treatments to improve pet health.
多家小型和大型公司的存在导致了竞争激烈的市场。这些公司提供跨细分市场和目标物种的广泛兽药。此外，市场参与者正在部署各种战略举措，例如研发、并购、区域扩张、合作伙伴关系和协作，以支持其增长目标。例如，2024 年 8 月，Elanco Animal Health 将投资 1.3 亿美元，将其位于堪萨斯州埃尔伍德的生物制品生产设施扩大 25,000 平方英尺，增强其单克隆抗体 (mAb) 平台。此次扩建预计到 2026 年将创造 70 个新就业岗位，将支持犬细小病毒单克隆抗体和未来犬皮肤病单克隆抗体的生产，强调该行业向基于抗体的治疗方法的转变，以改善宠物健康。

Recent Developments 最新动态

• In September 2024, Zoetis and Danone partnered to advance sustainable dairy farming through innovative genetic solutions to improve cow health and reduce environmental impacts. This collaboration will utilize Zoetis' genetic testing technologies, including the Dairy Wellness Profit Index, to help dairy producers breed resilient animals while aligning with increasing consumer demands for sustainable dairy products, ultimately enhancing the veterinary medicine market's role in promoting animal welfare and farm productivity.
  2024 年 9 月，硕腾和达能合作，通过创新的基因解决方案推进可持续奶牛养殖，改善奶牛健康并减少环境影响。此次合作将利用硕腾的基因检测技术，包括乳制品健康利润指数，帮助乳制品生产商培育有弹性的动物，同时满足消费者对可持续乳制品日益增长的需求，最终增强兽药市场在促进动物福利和农场生产力方面的作用。

• In August 2024, Boehringer Ingelheim India formed a strategic distribution partnership with Vvaan Lifesciences Pvt Ltd to enhance its pet parasiticide portfolio and expand its reach in India's pet health market, valued at around USD 124.51million. This collaboration aims to improve access to quality pet healthcare in Tier 2 and underserved cities, leveraging Vvaan's expertise to better serve these regions and elevate veterinary care standards across the country.
  2024年8月，勃林格殷格翰印度公司与Vvaan Lifesciences Pvt Ltd建立了战略分销合作伙伴关系，以增强其宠物杀虫剂产品组合，并扩大其在印度宠物健康市场（价值约1.2451亿美元）的影响力。此次合作旨在改善二线城市和服务欠缺城市获得优质宠物医疗保健的机会，利用 Vvaan 的专业知识更好地服务这些地区并提高全国的兽医护理标准。

• In June 2024, Trupanion and Boehringer Ingelheim entered into a strategic collaboration to enhance pet healthcare by improving access to quality treatment and disease management. This partnership will leverage both companies' expertise to facilitate early detection of pet health risks and support veterinary education, ultimately benefiting the veterinary medicine market by integrating innovative insurance solutions with advanced animal health treatments. Trupanion's unique ability to provide immediate payment to veterinarians will further streamline the healthcare process for pet owners.
  2024 年 6 月，Trupanion 和勃林格殷格翰达成战略合作，通过改善优质治疗和疾病管理的机会来增强宠物医疗保健。此次合作将利用两家公司的专业知识，促进宠物健康风险的早期发现并支持兽医教育，通过将创新的保险解决方案与先进的动物健康治疗相结合，最终使兽医市场受益。 Trupanion 向兽医提供即时付款的独特能力将进一步简化宠物主人的医疗保健流程。

• In March 2024, Merck Animal Health has received a positive opinion from the European Medicines Agency's CVMP for its NOBILIS MULTRIVA RT+IBm+ND+Gm+REOm+EDS vaccine, a 9-valent vaccine designed for chickens to protect against multiple viral infections, including Newcastle Disease, Infectious Bronchitis, and Egg Drop Syndrome. This vaccine, given in a low 0.3 ml dose, aims to reduce waste and streamline the vaccination process.

Global Veterinary Medicine Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global veterinary medicine market report based on product, animal type, route of administration, distribution channel, and region.

• Animal Type Outlook (Revenue, USD Million, 2018 - 2030)

  • Production Animals

    • Poultry

    • Pigs

    • Cattle

    • Sheep & Goats

    • Others

  • Companion Animals

    • Dogs

    • Cats

    • Horses

    • Others

• Product Outlook (Revenue, USD Million, 2018 - 2030)

  • Biologics

    • Vaccines

      • Modified/ Attenuated Live

      • Inactivated (Killed)

      • Other Vaccines

    • Other Biologics

  • Pharmaceuticals

    • Parasiticides

    • Anti-infectives

    • Anti-inflammatory

    • Analgesics

    • Others

  • Medicated Feed Additives

• Route of Administration Outlook (Revenue, USD Million, 2018 - 2030)

  • Oral

  • Injectable

  • Topical

  • Other Routes

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Veterinary Hospitals & Clinics

  • E-commerce

  • Offline Retail Stores

  • Others

• Regional Outlook (Revenue, USD Million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Netherlands

    • Norway

    • Denmark

    • Sweden

    • Rest of Europe

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

    • Rest of Asia Pacific

  • Latin America

    • Brazil

    • Mexico

    • Argentina

    • Rest of Latin America

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

    • Egypt

    • Israel

    • Rest of MEA